{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:17:08Z","timestamp":1789474628365,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00213-016-4453-0","type":"journal-article","created":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:25:20Z","timestamp":1475799920000},"page":"1499-1510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":174,"title":["Alterations of consciousness and mystical-type experiences after acute LSD in humans"],"prefix":"10.1007","volume":"234","author":[{"given":"Matthias E.","family":"Liechti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C.","family":"Dolder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,7]]},"reference":[{"key":"4453_CR1","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/0269881115609019","volume":"29","author":"FS Barrett","year":"2015","unstructured":"Barrett FS, Johnson MW, Griffiths RR (2015) Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. J Psychopharmacol 29:1182\u20131190","journal-title":"J Psychopharmacol"},{"key":"4453_CR2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/2045125314527985","volume":"4","author":"D Baumeister","year":"2014","unstructured":"Baumeister D, Barnes G, Giaroli G, Tracy D (2014) Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. Ther Adv Psychopharmacol 4:156\u2013169","journal-title":"Ther Adv Psychopharmacol"},{"key":"4453_CR3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 29:289\u2013299","journal-title":"J Psychopharmacol"},{"key":"4453_CR4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00213-014-3714-z","volume":"232","author":"RL Carhart-Harris","year":"2015","unstructured":"Carhart-Harris RL, Kaelen M, Whalley MG, Bolstridge M, Feilding A, Nutt DJ (2015) LSD enhances suggestibility in healthy volunteers. Psychopharmacology 232:785\u2013794","journal-title":"Psychopharmacology"},{"key":"4453_CR5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ (2016a) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3:619\u2013627","journal-title":"Lancet Psychiatry"},{"key":"4453_CR6","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1017\/S0033291715002901","volume":"46","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Kaelen M, Bolstridge M, Williams TM, Williams LT, Underwood R, Feilding A, Nutt DJ (2016b) The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med 46:1379\u20131390","journal-title":"Psychol Med"},{"key":"4453_CR7","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1073\/pnas.1518377113","volume":"113","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, Tagliazucchi E, Schenberg EE, Nest T, Orban C, Leech R, Williams LT, Williams TM, Bolstridge M, Sessa B, McGonigle J, Sereno MI, Nichols D, Hellyer PJ, Hobden P, Evans J, Singh KD, Wise RG, Curran HV, Feilding A, Nutt DJ (2016c) Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A 113:4853\u20134858","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4453_CR8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1503\/cmaj.1150082","volume":"188","author":"WJ Davenport","year":"2016","unstructured":"Davenport WJ (2016) Psychedelic and nonpsychedelic LSD and psilocybin for cluster headache. CMAJ 188:217","journal-title":"CMAJ"},{"key":"4453_CR9","volume-title":"LSD: R\u00fcckkehr in the Klinische Forschung","author":"MK Diesch","year":"2015","unstructured":"Diesch MK (2015) LSD: R\u00fcckkehr in the Klinische Forschung. Nachtschatten Verlag, Solothurn"},{"issue":"Suppl 2","key":"4453_CR10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-979351","volume":"31","author":"A Dittrich","year":"1998","unstructured":"Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31(Suppl 2):80\u201384","journal-title":"Pharmacopsychiatry"},{"key":"4453_CR11","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00216-014-8388-1","volume":"407","author":"PC Dolder","year":"2015","unstructured":"Dolder PC, Liechti ME, Rentsch KM (2015a) Development and validation of a rapid turboflow LC-MS\/MS method for the quantification of LSD and 2-oxo-3-hydroxy LSD in serum and urine samples of emergency toxicological cases. Anal Bioanal Chem 407:1577\u20131584","journal-title":"Anal Bioanal Chem"},{"key":"4453_CR12","doi-asserted-by":"publisher","unstructured":"Dolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME (2015b) Pharmacokinetics and concentration-effect relationship of oral LSD in humans. Int J Neuropsychopharmacol 19. doi: 10.1093\/ijnp\/pyv072","DOI":"10.1093\/ijnp\/pyv072"},{"key":"4453_CR13","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1038\/npp.2016.82","volume":"41","author":"PC Dolder","year":"2016","unstructured":"Dolder PC, Schmid Y, Mueller F, Borgwardt S, Liechti ME (2016) LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology 41:2638\u20132646","journal-title":"Neuropsychopharmacology"},{"key":"4453_CR14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473708666150107121331","volume":"7","author":"A Garcia-Romeu","year":"2015","unstructured":"Garcia-Romeu A, Griffiths RR, Johnson MW (2015) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev 7:157\u2013164","journal-title":"Curr Drug Abuse Rev"},{"key":"4453_CR15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202:513\u2013520","journal-title":"J Nerv Ment Dis"},{"key":"4453_CR16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881114555249","volume":"29","author":"P Gasser","year":"2015","unstructured":"Gasser P, Kirchner K, Passie T (2015) LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol 29:57\u201368","journal-title":"J Psychopharmacol"},{"key":"4453_CR17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1055\/s-2005-916185","volume":"38","author":"E Gouzoulis-Mayfrank","year":"2005","unstructured":"Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA (2005) Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 38:301\u2013311","journal-title":"Pharmacopsychiatry"},{"key":"4453_CR18","unstructured":"Griffiths R (2016) Overview of the Johns Hopkins psilocybin research project. Interdisciplinary Conference on Psychedelics Research, Amsterdam, June 3\u20135, 2016"},{"key":"4453_CR19","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187:268\u2013283 discussion 284-292","journal-title":"Psychopharmacology"},{"key":"4453_CR20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0269881108094300","volume":"22","author":"R Griffiths","year":"2008","unstructured":"Griffiths R, Richards W, Johnson M, McCann U, Jesse R (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14\u00a0months later. J Psychopharmacol 22:621\u2013632","journal-title":"J Psychopharmacol"},{"key":"4453_CR21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","volume":"218","author":"RR Griffiths","year":"2011","unstructured":"Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology 218:649\u2013665","journal-title":"Psychopharmacology"},{"key":"4453_CR22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer GR (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psych 68:71\u201378","journal-title":"Arch Gen Psych"},{"key":"4453_CR23","unstructured":"Guss J (2016) The NYU School of Medicine study on psilocybin-assisted therapy for treatment of existential distress in cancer patients: history, study structure, therapist training, outcome data. Interdisciplinary Conference on Psychedelic Research Amsterdam 3\u20135 June, 2016"},{"key":"4453_CR24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","volume":"172","author":"F Hasler","year":"2004","unstructured":"Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology 172:145\u2013156","journal-title":"Psychopharmacology"},{"key":"4453_CR25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00213-012-2761-6","volume":"224","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Liechti ME (2012) Effects of MDMA alone and after pretreatement with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex. Psychopharmacology 224:363\u2013376","journal-title":"Psychopharmacology"},{"key":"4453_CR26","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/clpt.2011.78","volume":"90","author":"CM Hysek","year":"2011","unstructured":"Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME (2011) The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (\"ecstasy\") in humans. Clin Pharmacol Ther 90:246\u2013255","journal-title":"Clin Pharmacol Ther"},{"key":"4453_CR27","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 28:983\u2013992","journal-title":"J Psychopharmacol"},{"key":"4453_CR28","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1007\/s00213-015-4014-y","volume":"232","author":"M Kaelen","year":"2015","unstructured":"Kaelen M, Barrett FS, Roseman L, Lorenz R, Family N, Bolstridge M, Curran HV, Feilding A, Nutt DJ, Carhart-Harris RL (2015) LSD enhances the emotional response to music. Psychopharmacology 232:3607\u20133614","journal-title":"Psychopharmacology"},{"key":"4453_CR29","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.euroneuro.2016.03.018","volume":"26","author":"M Kaelen","year":"2016","unstructured":"Kaelen M, Roseman L, Kahan J, Santos-Ribeiro A, Orban C, Lorenz R, Barrett FS, Bolstridge M, Williams T, Williams L, Wall MB, Feilding A, Muthukumaraswamy S, Nutt DJ, Carhart-Harris R (2016) LSD modulates music-induced imagery via changes in parahippocampal connectivity. Eur Neuropsychopharmacol 26:1099\u20131109","journal-title":"Eur Neuropsychopharmacol"},{"key":"4453_CR30","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","volume":"26","author":"TS Krebs","year":"2012","unstructured":"Krebs TS, Johansen PO (2012) Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 26:994\u20131002","journal-title":"J Psychopharmacol"},{"key":"4453_CR31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.12688\/f1000research.2-98.v1","volume":"2","author":"TS Krebs","year":"2013","unstructured":"Krebs TS, Johansen PO (2013) Over 30 million psychedelic users in the United States. F1000Res 2:98","journal-title":"F1000Res"},{"key":"4453_CR32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1126\/science.345.6192.18","volume":"345","author":"K Kupferschmidt","year":"2014","unstructured":"Kupferschmidt K (2014) High hopes. Science 345:18\u201323","journal-title":"Science"},{"key":"4453_CR33","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1002\/hbm.23234","volume":"37","author":"AV Lebedev","year":"2016","unstructured":"Lebedev AV, Kaelen M, Lovden M, Nilsson J, Feilding A, Nutt DJ, Carhart-Harris RL (2016) LSD-induced entropic brain activity predicts subsequent personality change. Hum Brain Mapp 37:3203\u20133213","journal-title":"Hum Brain Mapp"},{"key":"4453_CR34","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/0269881111420188","volume":"25","author":"KA MacLean","year":"2011","unstructured":"MacLean KA, Johnson MW, Griffiths RR (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 25:1453\u20131461","journal-title":"J Psychopharmacol"},{"key":"4453_CR35","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1468-5906.2012.01685.x","volume":"51","author":"KA MacLean","year":"2012","unstructured":"MacLean KA, Leoutsakos JM, Johnson MW, Griffiths RR (2012) Factor analysis of the Mystical Experience Questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. J Sci Study Relig 51:721\u2013737","journal-title":"J Sci Study Relig"},{"key":"4453_CR36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev 68:264\u2013355","journal-title":"Pharmacol Rev"},{"key":"4453_CR37","first-page":"149","volume":"5","author":"WN Pahnke","year":"1969","unstructured":"Pahnke WN (1969) Psychedelic drugs and mystical experience. Int Psychiatry Clin 5:149\u2013162","journal-title":"Int Psychiatry Clin"},{"key":"4453_CR38","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jama.1970.03170240060010","volume":"212","author":"WN Pahnke","year":"1970","unstructured":"Pahnke WN, Kurland AA, Unger S, Savage C, Grof S (1970) The experimental use of psychedelic (LSD) psychotherapy. JAMA 212:1856\u20131863","journal-title":"JAMA"},{"key":"4453_CR39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","volume":"14","author":"T Passie","year":"2008","unstructured":"Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008) The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 14:295\u2013314","journal-title":"CNS Neurosci Ther"},{"key":"4453_CR40","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","volume":"26","author":"A Rickli","year":"2016","unstructured":"Rickli A, Moning OD, Hoener MC, Liechti ME (2016) Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol 26:1327\u20131337","journal-title":"Eur Neuropsychopharmacol"},{"key":"4453_CR41","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1002\/hbm.23224","volume":"37","author":"L Roseman","year":"2016","unstructured":"Roseman L, Sereno MI, Leech R, Kaelen M, Orban C, McGonigle J, Feilding A, Nutt DJ, Carhart-Harris RL (2016) LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion. Hum Brain Mapp 37:3031\u20133040","journal-title":"Hum Brain Mapp"},{"key":"4453_CR42","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/0269881114542454","volume":"28","author":"Y Schmid","year":"2014","unstructured":"Schmid Y, Hysek CM, Simmler LD, Crockett MJ, Quednow BB, Liechti ME (2014) Differential effects of MDMA and methylphenidate on social cognition. J Psychopharmacol 28:847\u2013856","journal-title":"J Psychopharmacol"},{"key":"4453_CR43","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.biopsych.2014.11.015","volume":"78","author":"Y Schmid","year":"2015","unstructured":"Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Muller F, Borgwardt S, Liechti ME (2015) Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry 78:544\u2013553","journal-title":"Biol Psychiatry"},{"key":"4453_CR44","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/0269881116628430","volume":"30","author":"J Speth","year":"2016","unstructured":"Speth J, Speth C, Kaelen M, Schloerscheidt AM, Feilding A, Nutt DJ, Carhart-Harris RL (2016) Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. J Psychopharmacol 30:344\u2013353","journal-title":"J Psychopharmacol"},{"key":"4453_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2042","author":"AE Steuer","year":"2016","unstructured":"Steuer AE, Poetzsch M, Stock L, Eisenbeiss L, Schmid Y, Liechti ME, Kraemer T (2016) Development and validation of an ultra-fast and sensitive microflow liquid chromatography-tandem mass spectrometry (MFLC-MS\/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in humans. Drug Test Anal. doi: 10.1002\/dta.2042","journal-title":"Drug Test Anal"},{"key":"4453_CR46","doi-asserted-by":"crossref","first-page":"12374","DOI":"10.1111\/jne.12374","volume":"28","author":"P Strajhar","year":"2016","unstructured":"Strajhar P, Schmid Y, Liakoni E, Dolder PC, Rentsch KM, Kratschmar DV, Odermatt A, Liechti ME (2016) Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects. J Neuroendocrinol 28:12374","journal-title":"J Neuroendocrinol"},{"key":"4453_CR47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012412","volume":"5","author":"E Studerus","year":"2010","unstructured":"Studerus E, Gamma A, Vollenweider FX (2010) Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One 5:e12412","journal-title":"PLoS One"},{"key":"4453_CR48","doi-asserted-by":"crossref","first-page":"e30800","DOI":"10.1371\/journal.pone.0030800","volume":"7","author":"E Studerus","year":"2012","unstructured":"Studerus E, Gamma A, Kometer M, Vollenweider FX (2012) Prediction of psilocybin response in healthy volunteers. PLoS One 7:e30800","journal-title":"PLoS One"},{"key":"4453_CR49","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cub.2016.02.010","volume":"26","author":"E Tagliazucchi","year":"2016","unstructured":"Tagliazucchi E, Roseman L, Kaelen M, Orban C, Muthukumaraswamy SD, Murphy K, Laufs H, Leech R, McGonigle J, Crossley N, Bullmore E, Williams T, Bolstridge M, Feilding A, Nutt DJ, Carhart-Harris R (2016) Increased global functional connectivity correlates with LSD-induced ego dissolution. Curr Biol 26:1043\u20131050","journal-title":"Curr Biol"},{"key":"4453_CR50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.neuropsychologia.2016.04.005","volume":"88","author":"DB Terhune","year":"2016","unstructured":"Terhune DB, Luke DP, Kaelen M, Bolstridge M, Feilding A, Nutt D, Carhart-Harris R, Ward J (2016) A placebo-controlled investigation of synaesthesia-like experiences under LSD. Neuropsychologia 88:28\u201334","journal-title":"Neuropsychologia"},{"key":"4453_CR51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/02791072.1974.10471499","volume":"6","author":"IS Turek","year":"1974","unstructured":"Turek IS, Soskin RA, Kurland AA (1974) Methylenedioxyamphetamine (MDA)-subjective effects. J Psychoactive Drugs 6:7\u201314","journal-title":"J Psychoactive Drugs"},{"key":"4453_CR52","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","volume":"11","author":"FX Vollenweider","year":"2010","unstructured":"Vollenweider FX, Kometer M (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11:642\u2013651","journal-title":"Nat Rev Neurosci"},{"key":"4453_CR53","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/sj.npp.1301324","volume":"32","author":"FX Vollenweider","year":"2007","unstructured":"Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB (2007) The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology 32:1876\u20131887","journal-title":"Neuropsychopharmacology"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-016-4453-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-016-4453-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-016-4453-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T10:03:29Z","timestamp":1568455409000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-016-4453-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,7]]},"references-count":53,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["4453"],"URL":"https:\/\/doi.org\/10.1007\/s00213-016-4453-0","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,7]]}}}